Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs Zoetis Inc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.6, while Zoetis Inc trades at $74.43 (market cap $31.59B). The key difference: Zoetis Inc pays a 2.81% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| QDTE | ZTS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $156.76 |
52-Week Low | $26.85 | $71.91 |
Market Cap | — | $31.59B |
Enterprise Value | — | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $29.22, up 0.31% on the day, with technical indicators signaling a bearish trend. The ETF employs a weekly covered call strategy on the Innovation-100 index, generating high distribution yields. Recent news highlights scrutiny over its fee structure and yield sustainability amid declining volatility. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook is cautious due to bearish technicals and yield compression risks. Opportunities exist for income-focused investors seeking weekly distributions, but risks include fee drag and volatility dependence. Investor sentiment is mixed, with media questioning yield math while acknowledging competitive returns in certain periods.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
